Meghann P. Mcmanus

Hematology | Oncology

330 23rd Ave N Ste 100
Nashville, TN 37203

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Incidence of Human Leukocyte Antigen (HLA) Class I Antibodies and Impact on Platelet Engraftment, Transfusions and Bleeding in Recipients of Gene Therapy for Sickle Cell Disease and Transfusion Dependent Beta Thalassemia.

Incidence of Human Leukocyte Antigen (HLA) Class I Antibodies and Impact on Platelet Engraftment, Transfusions and Bleeding in Recipients of Gene Therapy for Sickle Cell Disease and Transfusion Dependent Beta Thalassemia.

Journal: Transplantation and cellular therapy

Published: July 02, 2026

CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia.

CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia.

Journal: The New England journal of medicine

Published: April 03, 2026

Prime Editing for p47phox-Deficient Chronic Granulomatous Disease.

Prime Editing for p47phox-Deficient Chronic Granulomatous Disease.

Journal: The New England journal of medicine

Published: December 08, 2025

Safety and Feasibility of Fertility Preservation and Fertility Outcomes in Patients with Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Undergoing Gene Therapy.

Safety and Feasibility of Fertility Preservation and Fertility Outcomes in Patients with Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Undergoing Gene Therapy.

Journal: Transplantation and cellular therapy

Published: June 01, 2025

Best Practices in Gene Therapy for Sickle Cell Disease and Transfusion-dependent β-Thalassemia.

Best Practices in Gene Therapy for Sickle Cell Disease and Transfusion-dependent β-Thalassemia.

Journal: Transplantation and cellular therapy

Published: February 18, 2025

CRISPR-based gene therapy for the induction of fetal hemoglobin in sickle cell disease.

CRISPR-based gene therapy for the induction of fetal hemoglobin in sickle cell disease.

Journal: Expert review of hematology

Published: November 13, 2024

Phase I Study of Clofarabine and 2-Gy Total Body Irradiation as a Nonmyeloablative Preparative Regimen for Hematopoietic Stem Cell Transplantation in Pediatric Patients with Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia Consortium Study.

Phase I Study of Clofarabine and 2-Gy Total Body Irradiation as a Nonmyeloablative Preparative Regimen for Hematopoietic Stem Cell Transplantation in Pediatric Patients with Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia Consortium Study.

Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

Published: February 09, 2017

Deficient Neutrophil Extracellular Trap Formation in Patients Undergoing Bone Marrow Transplantation.

Deficient Neutrophil Extracellular Trap Formation in Patients Undergoing Bone Marrow Transplantation.

Journal: Frontiers in immunology

Published: April 27, 2016

Autoimmunity due to RAG deficiency and estimated disease incidence in RAG1/2 mutations.

Autoimmunity due to RAG deficiency and estimated disease incidence in RAG1/2 mutations.

Journal: The Journal of allergy and clinical immunology

Published: July 26, 2013

Safety of high dose trivalent inactivated influenza vaccine in pediatric patients with acute lymphoblastic leukemia.

Safety of high dose trivalent inactivated influenza vaccine in pediatric patients with acute lymphoblastic leukemia.

Journal: Pediatric blood & cancer

Published: July 05, 2013

Comparison of pre-cryopreserved and post-thaw-and-wash-nucleated cell count on major outcomes following unrelated cord blood transplant in children.

Comparison of pre-cryopreserved and post-thaw-and-wash-nucleated cell count on major outcomes following unrelated cord blood transplant in children.

Journal: Pediatric transplantation

Published: April 27, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026